

Rius Medical
followers
Primary tabs
About your organization / profile
The Elevator Pitch: Rius Medical is developing Advanced Manufacturing to help patients with cancer and FOUR rare diseases of metabolism, like Phenylketonuria (PKU) by solving the problem of Drug Delivery through reprogramming stem cells. In doing so, Rius Medical unlocks Digital Health with Diagnostic alongside Therapeutics!
In Rius Medical, Investor(s) shall find a founder with experience and expertise in healthcare, enterprise AI and industrial technology space. Benchmark at “43% BioMarin Palynziq” where Palynziq (market-approved) is at USD 267,000 per year per patient, the Rius Medical product on EU market is at USD 114,973 per year per patient, the product represents an annual market size in Denmark of USD 50 million; in Scandinavia of USD 199 million and in EU of USD 5 billion – same for USA. [For rare disease of metabolism, Phenylketonuria (PKU), EU has 44,800x PKU Patients and USA has 33,600x PKU Patients that enterprise AI ensures Diagnostic alongside Therapeutics!] So rare disease of metabolism Phenylketonuria (PKU) with enzyme cargo red blood cells vs. FDA and EMA approved BioMarin’s enzyme substitution therapy to treat PKU - i.e. daily injection BioMarin Palynziq at 365x injections per year per patient to Rius Medical 4x injections per year per patient.
Therapeutics USA: San Francisco AllCells supplies 1x CD34+ stem cells for Rius Medical engineering and culture at Boulder Colorado US CDMO AGC Biologics for OUT-Licensing option to San Francisco Quince Therapeutics, focused on acquiring, developing, and commercializing innovative therapeutics that transform the lives of patients suffering from debilitating and rare diseases! Out-Licensing the therapeutics enables Rius Medical to focus on enterprise AI and industrial technology for on-time-delivery to patients. Is it a ridiculous idea for an investor-partnership that brings enterprise AI in providing advanced therapies to patients?
Rius Medical is seeking EUR 500,000 bridge financing for early start January 2025 onwards – supporting the exploration of bold ideas for radically new technologies. Rius Medical proposal has a convincing long-term vision of a radically new technology with a transformative positive effect to the economy and society. Essentially this implies the involvement of Artificial Intelligence (AI) as enterprise AI alongside therapeutic red blood cells!
Building the future of medicine, therapeutic red blood cells as radically better drugs unlocks Digital Health with Diagnostic alongside Therapeutics! Enterprise AI is the use of artificial intelligence (AI) to make businesses less manual, less time-consuming and less prone to human error. A key distinction between enterprise AI and AI generally is that enterprise AI focuses on addressing specific high-value use cases at large scale, where the application of AI embedded into business processes produces meaningful value [on-time-delivery to patients for 78-days treatment of therapeutic red blood cells].
An EXIT opportunity at year 2 for early investors joining this Series A investment round of up to 1 million euro and post-money valuation at 5 million euro will result on “Ticket ONE investment” of EUR 500,000 at 10% ownership as EUR 1,8 million dividends if not EUR 10 million EXIT option by December 2026 [20x ROI to investor(s)]. My mindset of highest possible return is benchmark to US Aeglea BioTherapeutics receiving USD 21.5 million upfront with up to approximately USD 130 million in milestone payments and royalties from Sweden Immedica.
Our Fundraising
Amount sought: 500 000 €
Turning academic discovery into cost competitive products produced at large scale, as an innovator, Rius Medical focuses on Cell therapy - the transfer of cellular materials into a patient for therapeutic purposes! That’s “enzyme cargo” red blood cells with building large-scale production facilities for protein production as “enzyme cargo”. Cells are collected from 1x donor sample to create a master cell bank (MCB). The MCB is then used as the source to create cell populations that are processed according to the demands of the specific therapy. [It is not iPSC but bone marrow derived stem cells engineered as MCB for cultured red blood cells inclusive biologic enzyme cargo].
Amount wanted:
500 000 €
Amount confirmed:
0 €
Intentions:
500 000 €
Network (0)
There are no organizations in the network.
Recent activities

Denis Demarais (Founder and CEO, Rius Medical) has published an article on Rius Medical's page.

Denis Demarais (Founder and CEO, Rius Medical) has published an article on Rius Medical's page.

Rius Medical has updated its fundraising.

Rius Medical has published fundraising documents.

Rius Medical has cancelled its fundraising.

Rius Medical has updated its fundraising.

Rius Medical has published fundraising documents.

Rius Medical has updated its fundraising.

Rius Medical has taken its partnership search offline: Equity investor for 30.000 euro.

Rius Medical has taken its fundraising offline.